BR112022014160A2 - Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau - Google Patents

Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau

Info

Publication number
BR112022014160A2
BR112022014160A2 BR112022014160A BR112022014160A BR112022014160A2 BR 112022014160 A2 BR112022014160 A2 BR 112022014160A2 BR 112022014160 A BR112022014160 A BR 112022014160A BR 112022014160 A BR112022014160 A BR 112022014160A BR 112022014160 A2 BR112022014160 A2 BR 112022014160A2
Authority
BR
Brazil
Prior art keywords
zinc finger
transcription factors
finger protein
protein transcription
tau expression
Prior art date
Application number
BR112022014160A
Other languages
English (en)
Inventor
Zeitler Bryan
Hatami Asa
Zhang Lei
Original Assignee
Sangamo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics Inc filed Critical Sangamo Therapeutics Inc
Publication of BR112022014160A2 publication Critical patent/BR112022014160A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

FATORES DE TRANSCRIÇÃO DE PROTEÍNA DEDO DE ZINCO PARA REPRIMIR A EXPRESSÃO DE TAU. A presente invenção refere-se a proteínas de fusão dedo de zinco que inibem a expressão de tau no sistema nervoso, e aos métodos de uso das proteínas no tratamento de doenças neurodegenerativas tais como o mal de Alzheimer, a demência frontotemporal e outras tauopatias.
BR112022014160A 2020-01-22 2021-01-22 Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau BR112022014160A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062964501P 2020-01-22 2020-01-22
PCT/US2021/014780 WO2021151012A1 (en) 2020-01-22 2021-01-22 Zinc finger protein transcription factors for repressing tau expression

Publications (1)

Publication Number Publication Date
BR112022014160A2 true BR112022014160A2 (pt) 2022-09-13

Family

ID=74661487

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022014160A BR112022014160A2 (pt) 2020-01-22 2021-01-22 Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau

Country Status (14)

Country Link
US (1) US20230242602A1 (pt)
EP (1) EP4093754A1 (pt)
JP (1) JP2023511908A (pt)
KR (1) KR20220131273A (pt)
CN (1) CN115210251A (pt)
AR (1) AR121118A1 (pt)
AU (1) AU2021209699A1 (pt)
BR (1) BR112022014160A2 (pt)
CA (1) CA3168805A1 (pt)
IL (1) IL294535A (pt)
MX (1) MX2022008953A (pt)
TW (1) TW202134288A (pt)
UY (1) UY39036A (pt)
WO (1) WO2021151012A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3043635A1 (en) 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69534629D1 (de) 1994-01-18 2005-12-29 Scripps Research Inst Derivate von zinkfingerproteinen und methoden
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
ATE407205T1 (de) 1994-08-20 2008-09-15 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
DE69942334D1 (de) 1998-03-02 2010-06-17 Massachusetts Inst Technology Poly-zinkfinger-proteine mit verbesserten linkern
ATE355368T1 (de) 2000-01-24 2006-03-15 Gendaq Ltd Nucleinsäure bindende polypeptide gekennzeichnet durch flexible linker verbundene nucleinsäuredomäne
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
US20030044787A1 (en) 2000-05-16 2003-03-06 Joung J. Keith Methods and compositions for interaction trap assays
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
AU2002336373A1 (en) 2001-08-20 2003-03-03 The Scripps Research Institute Zinc finger binding domains for cnn
WO2009154686A1 (en) 2008-05-28 2009-12-23 Sangamo Biosciences, Inc. Compositions for linking dna-binding domains and cleavage domains
EP3636766A1 (en) 2010-05-03 2020-04-15 Sangamo Therapeutics, Inc. Compositions for linking zinc finger modules
CA3131284C (en) 2013-08-28 2023-09-19 David Paschon Compositions for linking dna-binding domains and cleavage domains
EP3929279A1 (en) 2014-03-18 2021-12-29 Sangamo Therapeutics, Inc. Methods and compositions for regulation of zinc finger protein expression
WO2017011556A1 (en) * 2015-07-13 2017-01-19 The General Hospital Corporation Rare phosphorylated high molecular weight (hmw) tau species that are involved in neuronal uptake and propagation and applications thereof
EP3411056A4 (en) 2016-02-02 2019-10-02 Sangamo Therapeutics, Inc. COMPOUNDS FOR NETWORKING DNA BINDING DOMAINS AND SPLITTING DOMAINS
SG10201913948PA (en) 2016-08-24 2020-03-30 Sangamo Therapeutics Inc Engineered target specific nucleases
CA3043635A1 (en) * 2016-12-01 2018-06-07 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
CN113195002A (zh) 2018-10-02 2021-07-30 桑格摩生物治疗股份有限公司 工程化的遗传调节物
CA3115156A1 (en) 2018-10-02 2020-04-09 Sangamo Therapeutics, Inc. Methods and compositions for modulation of tau proteins

Also Published As

Publication number Publication date
US20230242602A1 (en) 2023-08-03
MX2022008953A (es) 2022-08-15
WO2021151012A1 (en) 2021-07-29
EP4093754A1 (en) 2022-11-30
JP2023511908A (ja) 2023-03-23
IL294535A (en) 2022-09-01
CA3168805A1 (en) 2021-07-29
UY39036A (es) 2021-08-31
TW202134288A (zh) 2021-09-16
KR20220131273A (ko) 2022-09-27
AR121118A1 (es) 2022-04-20
CN115210251A (zh) 2022-10-18
AU2021209699A1 (en) 2022-07-21

Similar Documents

Publication Publication Date Title
ECSP20081591A (es) Proteínas de fusión que comprenden progranulina
BR112019005587A2 (pt) proteínas de ligação recombinantes e sua utilização
BR112018011308A2 (pt) anticorpos de peptídeo de beta amiloide anti-n3pglu e usos dos mesmos
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
CR8978A (es) Proteinas de fusion de dominio de union
BR112019006887A2 (pt) ativadores do fluxo autofágico e fosfolipase d e depuração de agregado proteico, incluindo tau e tratamento de proteinopatias
BR112022012230A2 (pt) Variantes de progranulina
BR112018013084A2 (pt) tratamentos de combinação compreendendo a administração de imidazopirazinonas
BR112019011462A2 (pt) peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica.
CL2020000070A1 (es) Agentes, usos y métodos para el tratamiento.
CL2018002430A1 (es) Proteínas de fusión de enzimas lisosomales terapéuticas dirigidas, formulaciones asociadas y usos de las mismas
BR112022021743A2 (pt) Compostos e métodos direcionando a interleucina-34
EA201990593A1 (ru) Непрерывный способ для снижения гетерогенности терапевтического белка
BR112021021213A2 (pt) Administração heteróloga de vacinas de tau
BR112022014160A2 (pt) Fatores de transcrição de proteína dedo de zinco para reprimir a expressão de tau
CO2021013171A2 (es) Compuestos y composiciones como moduladores de la señalización de tlr
CY1124821T1 (el) Ιγμεσινη για χρηση στη θεραπεια της νοσου του αλτσχαιμερ
EA202092305A1 (ru) Соединения в качестве модуляторов сигнализации tlr2
AR127484A1 (es) Compuestos y métodos dirigidos a interleucina-34
ECSP22049014A (es) Variantes de progranulina
UY39450A (es) Nuevos factores de transcripción de la proteína de dedo de zinc para reprimir la expresión de alfa- sinucleina
BR112023022999A2 (pt) Fusões peptídeo-fc para tratar distúrbios amiloides
AR120151A1 (es) FACTORES DE TRANSCRIPCIÓN DE PROTEÍNAS DE DEDOS DE ZINC PARA LA REPRESIÓN DE LA EXPRESIÓN DE a-SINUCLEÍNA
MX2019013717A (es) Plasma de origen animal o fracciones del mismo para usarse en el tratamiento contra trastornos del deterioro cognitivo en humanos y animales de compañia.
CA3156258A1 (en) ZINC FINGER PROTEIN TRANSCRIPTION FACTORS TO REPRESS ALPHA-SYNUCLEIN EXPRESSION

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]